Screener
Jazz Pharmaceuticals JAZZ Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
| Deferred tax liabilities, net | 547.7 | 594.5 |
| Other non-current liabilities | 161.5 | 124.4 |
| Commitments and contingencies (Note 10) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's long-term debt?
- Jazz Pharmaceuticals (JAZZ) reported long-term debt of $4.32B in Q1 2026.
- How has Jazz Pharmaceuticals's long-term debt changed year-over-year?
- Jazz Pharmaceuticals's long-term debt decreased by 19.0% year-over-year, from $5.34B to $4.32B.
- What is the long-term trend for Jazz Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's long-term debt has grown at a 18.5% compound annual growth rate (CAGR), from $1.85B to $4.33B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Jazz Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude